272 related articles for article (PubMed ID: 34338389)
1. Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.
Rudolph KE; Shulman M; Fishman M; Díaz I; Rotrosen J; Nunes EV
Addiction; 2022 Mar; 117(3):637-645. PubMed ID: 34338389
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.
Rudolph KE; Williams NT; Goodwin ATS; Shulman M; Fishman M; Díaz I; Luo S; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2022 Oct; 239():109609. PubMed ID: 36075154
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
4. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
[TBL] [Abstract][Full Text] [Related]
5. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
6. Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
Rudolph KE; Díaz I; Luo SX; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2021 Nov; 228():109031. PubMed ID: 34534863
[TBL] [Abstract][Full Text] [Related]
7. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
Randesi M; Rotrosen J; Nunes EV; Lee JD; Novo P; Levran O; Ott J; Pavlicova M; Scodes J; Kreek MJ
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):761-768. PubMed ID: 32851876
[No Abstract] [Full Text] [Related]
8. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
[TBL] [Abstract][Full Text] [Related]
9. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
10. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
11. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
13. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
[TBL] [Abstract][Full Text] [Related]
16. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Greiner MG; Shulman M; Choo TH; Scodes J; Pavlicova M; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 Dec; 131():108447. PubMed ID: 34098301
[TBL] [Abstract][Full Text] [Related]
17. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
[TBL] [Abstract][Full Text] [Related]
19. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
Haeny AM; Montgomery L; Burlew AK; Campbell ANC; Scodes J; Pavlicova M; Rotrosen J; Nunes E
Addict Behav; 2020 Nov; 110():106514. PubMed ID: 32619868
[TBL] [Abstract][Full Text] [Related]
20. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
